Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck Cancer DOI
Lova Sun, Danielle Candelieri-Surette, Tori Anglin-Foote

et al.

JAMA Otolaryngology–Head & Neck Surgery, Journal Year: 2022, Volume and Issue: 148(11), P. 1022 - 1022

Published: Sept. 22, 2022

Importance Cetuximab-based and carboplatin-based chemoradiotherapy (CRT) are often used for patients with locally advanced head neck cancer who ineligible cisplatin. There no prospective head-to-head data comparing cetuximab-based regimens radiosensitization. Objective To compare survival CRT in squamous cell carcinoma (HNSCC). Design, Setting, Participants This cohort study included US veterans received a diagnosis of HNSCC between January 2006 December 2020 were treated systemic therapy radiation. Data cutoff was March 1, 2022 analysis conducted from April-May 2022. Exposures Cisplatin, cetuximab, or as captured VA medication registry. Main Outcomes Measures Overall by estimated using Kaplan-Meier methods. We propensity score inverse probability weighting to achieve covariate balance cetuximab-treated carboplatin-treated Cox regression estimate cause-specific hazard ratios death associated carboplatin vs cetuximab. also performed subgroup analyses oropharynx nonoropharynx primary sites. Results A total 8290 (median [IQR] age, 63 [58-68] years; 8201 men [98.9%]; 1225 [15.8%] Black African American 6424 [82.6%] White individuals) nonmetastatic cisplatin (5566 [67%]), (1231 [15%]), cetuximab (1493 [18%]). Compared cisplatin-treated patients, older worse performance status scores higher comorbidity burden. Median (IQR) overall 74.4 (22.3-162.2) months radiotherapy (RT), 43.4 (15.3-123.8) RT, 31.1 (12.4-87.8) RT. After weighting, improved compared (cause-specific ratio, 0.85; 95% CI, 0.78-0.93; P = .001). difference prominent the subgroup. Conclusions Relevance In this veteran population undergoing treatment CRT, almost third receive matching, 15% improvement suggesting that may be preferred radiosensitizer, particularly cancers.

Language: Английский

Advances in HPV‐associated tumor management: Therapeutic strategies and emerging insights DOI

Xiangjin Gong,

Hao Chi, Zhijia Xia

et al.

Journal of Medical Virology, Journal Year: 2023, Volume and Issue: 95(7)

Published: July 1, 2023

Abstract With the rapid increase in incidence of cervical cancer, anal cancer and other cancers, human papillomavirus (HPV) infection has become a growing concern. Persistent with high‐risk HPV is major cause malignant tumors. In addition, microbiota viruses such as immunodeficiency virus, herpes simplex Epstein–Barr virus are closely associated infection. The limited effectiveness existing treatments for HPV‐associated tumors high rates recurrence metastasis patients create an urgent need novel effective approaches. recent years, vaccine coverage increased can reduce serious adverse events. Overall, this article provides comprehensive overview biology, microbiome, viral interactions development, highlighting more approach to prevention treatment. Current emerging HPV‐related control treatment strategies also further explored.

Language: Английский

Citations

40
Human Papillomavirus Epidemiology and Prevention: Is There Still a Gender Gap? DOI Creative Commons
Giovanna Milano, Giovanni Guarducci, Nicola Nante

et al.

Vaccines, Journal Year: 2023, Volume and Issue: 11(6), P. 1060 - 1060

Published: June 4, 2023

Background and aim: Human papillomavirus (HPV) is sexually transmitted, one of the three most common transmitted infections (STIs) in both males females, viral STI. A crucial public health strategy to protect people against HPV vaccination, which has shown its effectiveness preventing HPV-related diseases. Presently, types vaccines are available (bivalent, quadrivalent, nonvalent), they all target two oncogenic virus genotypes (HPV 16 18). In recent years, need implement vaccination programmes that include genders been discussed order achieve herd immunity HPV. To date, only a few countries have included young their programmes. Thus, our objective with this review provide an overview epidemiology prevention strategies report latest findings from scientific literature.

Language: Английский

Citations

30
Mitochondrial metabolism: a predictive biomarker of radiotherapy efficacy and toxicity DOI
Farzad Taghizadeh‐Hesary, Mohammad Houshyari, Mohammad Farhadi

et al.

Journal of Cancer Research and Clinical Oncology, Journal Year: 2023, Volume and Issue: 149(9), P. 6719 - 6741

Published: Jan. 31, 2023

Language: Английский

Citations

29
Analytical Validation of NavDx, a cfDNA-Based Fragmentomic Profiling Assay for HPV-Driven Cancers DOI Creative Commons
Alicia Gunning, Sunil Kumar,

Cassin Kimmel Williams

et al.

Diagnostics, Journal Year: 2023, Volume and Issue: 13(4), P. 725 - 725

Published: Feb. 14, 2023

The NavDx® blood test analyzes tumor tissue modified viral (TTMV)-HPV DNA to provide a reliable means of detecting and monitoring HPV-driven cancers. has been clinically validated in large number independent studies integrated into clinical practice by over 1000 healthcare providers at 400 medical sites the US. This Clinical Laboratory Improvement Amendments (CLIA), high complexity laboratory developed test, also accredited College American Pathologists (CAP) New York State Department Health. Here, we report detailed analytical validation NavDx assay, including sample stability, specificity as measured limits blank (LOBs), sensitivity illustrated via detection quantitation (LODs LOQs). LOBs were 0-0.32 copies/μL, LODs 0-1.10 LOQs <1.20-4.11 demonstrating data provided NavDx. In-depth evaluations accuracy intra- inter-assay precision shown be well within acceptable ranges. Regression analysis revealed degree correlation between expected effective concentrations, excellent linearity (R2 = 1) across broad range analyte concentrations. These results demonstrate that accurately reproducibly detects circulating TTMV-HPV DNA, which aid diagnosis surveillance

Language: Английский

Citations

27
HPV-related diseases in male patients: an underestimated conundrum DOI Creative Commons
Andrea Garolla, Andrea Graziani, Giuseppe Grande

et al.

Journal of Endocrinological Investigation, Journal Year: 2023, Volume and Issue: 47(2), P. 261 - 274

Published: Sept. 28, 2023

Abstract Purpose Human papillomavirus (HPV) infection is the most common sexually transmitted disease, in males and females worldwide. While role of HPV female diseases well known largely studied, have negligibly been included these programs, also because proportion women suffering dying from HPV-related much larger than men. The aim this review to focus on male patients. Methods We performed a literature analysis electronic database PubMed. considered randomized trials, observational retrospective studies, original articles having as topic relationship between following items: oral, anal penile cancers, warts, condylomas, infertility, altered sperm parameters, anti-sperm antibodies (ASA). experimental vitro studies focused effects oocyte fertilization, blastocyst development, trophoblastic cell invasiveness. In addition, describing adjuvant administration vaccination possible strategy promote clearance semen infected were included. Results Regarding head neck diseases, important non-neoplastic disease recurrent respiratory papillomatosis (RRP). neoplastic cancers attributable has increased dramatically nowadays, it thought that half squamous carcinomas (HNSCCs) cases United States are caused by with high-risk HPV. noteworthy andrological practice too. It was described high prevalence, ranging 50 70%, shaft, glans penis/coronal sulcus, scrotal, perianal, regions. Moreover, patients, associated, among other cancers. reported about 10% men general population 16% unexplained although data seem widely underestimated according clinical experience. particular, seems be related asthenozoospermia (ASAs). Conclusions represents health problem detrimental social public impact. Despite evidence, little done date young males.

Language: Английский

Citations

25
The complexity of human papilloma virus in cancers: a narrative review DOI Creative Commons

Vahideh Hamidi Sofiani,

Parsa Veisi,

Mohammad Rezaei Zadeh Rukerd

et al.

Infectious Agents and Cancer, Journal Year: 2023, Volume and Issue: 18(1)

Published: Feb. 26, 2023

Abstract Among human tumorigenic viruses, the role of Human papillomavirus (HPV) has been proven as one most important oncoviruses that are associated with a large number cancers. Most cancers genital area such cervical and anal cancer caused by HPV, in many other cancers, colorectal, gastric, liver, esophageal, urinary bladder, head neck it is considered risk factors. Our search was conducted for published researches between 2000 2022 using several international databases including Scopus, PubMed, Web Science well Google scholar. We also evaluated additional evidence from relevant articles. It demonstrated HPV can promote tumorigenesis via focusing on genes, proteins, signaling pathways, E6 E7 oncoproteins inhibiting two crucial tumor suppressors, P53 Rb. The following study performed to investigate different malignant under influence infection changes molecular factors infection.

Language: Английский

Citations

23
Advanced technologies towards improved HPV diagnostics DOI Creative Commons
Martin Bartošík, Ludmila Moráňová, Nasim Izadi

et al.

Journal of Medical Virology, Journal Year: 2024, Volume and Issue: 96(2)

Published: Jan. 31, 2024

Abstract Persistent infection with high‐risk types of human papillomaviruses (HPV) is a major cause cervical cancer, and an important factor in other malignancies, for example, head neck cancer. Despite recent progress screening vaccination, the incidence mortality are still relatively high, especially low‐income countries. The financial burden associated treatment could be decreased if simple, rapid, inexpensive technology HPV testing becomes available, targeting individuals further monitoring increased risk developing Commercial tests available market often expensive, time‐consuming, require sophisticated instrumentation, which limits their more widespread utilization. To address these challenges, novel technologies being implemented also diagnostics that include isothermal amplification techniques, lateral flow assays, CRISPR‐Cas‐based systems, as well microfluidics, paperfluidics lab‐on‐a‐chip devices, ideal point‐of‐care decentralized settings. In this review, we first evaluate current commercial tests, followed by description advanced technologies, explanation principles, critical evaluation strengths weaknesses, suggestions possible implementation into medical diagnostics.

Language: Английский

Citations

12
The potential and promise for clinical application of adoptive T cell therapy in cancer DOI Creative Commons
Yinqi Li,

Yeteng Zheng,

Taiqing Liu

et al.

Journal of Translational Medicine, Journal Year: 2024, Volume and Issue: 22(1)

Published: May 1, 2024

Abstract Adoptive cell therapy has revolutionized cancer treatment, especially for hematologic malignancies. T cells are the most extensively utilized in adoptive therapy. Currently, tumor-infiltrating lymphocytes, receptor-transgenic and chimeric antigen receptor three main therapies. Tumor-infiltrating lymphocytes kill tumors by reinfusing enlarged that naturally target tumor-specific antigens into patient. have ability to specifically destroy tumor via precise recognition of exogenous receptors with major histocompatibility complex. Chimeric transfer genes specific structural domains activation signals cells, allowing attack without assistance Many barriers been demonstrated affect clinical efficacy therapy, such as heterogeneity loss, hard trafficking infiltration, immunosuppressive microenvironment exhaustion. Several strategies improve explored, including multispecific combination immune checkpoint blockade, targeting microenvironment, etc. In this review, we will summarize current status application, followed bottlenecks addition, discuss promising result even more incredible advancements solid if aforementioned problems can be handled. Graphical abstract

Language: Английский

Citations

12
High‐risk HPV oncoproteins E6 and E7 and their interplay with the innate immune response: Uncovering mechanisms of immune evasion and therapeutic prospects DOI Creative Commons
Irene Lo Cigno, Federica Calati, Carlo Girone

et al.

Journal of Medical Virology, Journal Year: 2024, Volume and Issue: 96(6)

Published: May 24, 2024

Human papillomaviruses (HPVs) are double-stranded DNA (dsDNA) tumor viruses causally associated with 5% of human cancers, comprising both anogenital and upper aerodigestive tract carcinomas. Despite the availability prophylactic vaccines, HPVs continue to pose a significant global health challenge, primarily due inadequate vaccine access coverage. These can establish persistent infections by evading intrinsic defenses infected tissues extrinsic provided professional innate immune cells. Crucial for their evasion strategies is unique intraepithelial life cycle, which effectively shields them from host detection. Thus, aimed at reactivating response within or transformed epithelial cells, particularly through production type I interferons (IFNs) lymphocyte-recruiting chemokines, considered viable solutions counteract adverse effects these oncogenic viruses. This review focuses on complex interplay between high-risk HPV oncoproteins E6 E7 in cells HPV-associated cancers. In particular, it details molecular mechanisms modulate response, highlighting progress our comprehension processes. It also examines forward-looking that exploit system ameliorate existing anticancer therapies, thereby providing crucial insights into future therapeutic developments.

Language: Английский

Citations

10
Immune escape of head and neck cancer mediated by the impaired MHC-I antigen presentation pathway DOI
Xiaobo Luo, Yan Qiu, Zackary R. Fitzsimonds

et al.

Oncogene, Journal Year: 2024, Volume and Issue: 43(6), P. 388 - 394

Published: Jan. 4, 2024

Language: Английский

Citations

9